- Home
- TRMD vs BLTE Comparison
TRMD vs BLTE Comparison
Compare TRMD & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRMD
- BLTE
- Stock Information
- Founded
- TRMD 1889
- BLTE 2018
- Country
- TRMD United Kingdom
- BLTE United States
- Employees
- TRMD N/A
- BLTE N/A
- Industry
- TRMD Marine Transportation
- BLTE Biotechnology: Pharmaceutical Preparations
- Sector
- TRMD Consumer Discretionary
- BLTE Health Care
- Exchange
- TRMD Nasdaq
- BLTE Nasdaq
- Market Cap
- TRMD 1.9B
- BLTE 1.7B
- IPO Year
- TRMD N/A
- BLTE 2022
- Fundamental
- Price
- TRMD $18.91
- BLTE $57.37
- Analyst Decision
- TRMD Buy
- BLTE Strong Buy
- Analyst Count
- TRMD 1
- BLTE 4
- Target Price
- TRMD $48.00
- BLTE $96.33
- AVG Volume (30 Days)
- TRMD 948.9K
- BLTE 27.8K
- Earning Date
- TRMD 03-06-2025
- BLTE 03-10-2025
- Dividend Yield
- TRMD 30.93%
- BLTE N/A
- EPS Growth
- TRMD N/A
- BLTE N/A
- EPS
- TRMD 7.70
- BLTE N/A
- Revenue
- TRMD $1,641,593,000.00
- BLTE N/A
- Revenue This Year
- TRMD N/A
- BLTE N/A
- Revenue Next Year
- TRMD N/A
- BLTE N/A
- P/E Ratio
- TRMD $2.55
- BLTE N/A
- Revenue Growth
- TRMD 3.90
- BLTE N/A
- 52 Week Low
- TRMD $17.77
- BLTE $31.01
- 52 Week High
- TRMD $40.47
- BLTE $86.53
- Technical
- Relative Strength Index (RSI)
- TRMD 38.99
- BLTE 48.86
- Support Level
- TRMD $19.11
- BLTE $55.90
- Resistance Level
- TRMD $19.64
- BLTE $58.54
- Average True Range (ATR)
- TRMD 0.63
- BLTE 2.70
- MACD
- TRMD -0.11
- BLTE 0.24
- Stochastic Oscillator
- TRMD 1.27
- BLTE 52.14
About TRMD TORM plc
TORM PLC operates as a shipping company. The company owns and operates product tankers. It is engaged in the transportation of refined oil products The company transports clean petroleum products including gasoline, jet fuel, naphtha, and diesel oil, as well as other clean products. Its segments include the Tanker segment, and Marine Exhaust segment.
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.